We'll have to see about the new test. The question still remains: do you think that Onko-Sure can replace CEA with its higher specificity and sensitivity;stage I/II detection; MUCH cheaper price; and with draw backs that are the same or similar to CEA? Regardless of how poor Onko-Sure is, it is better than CEA and will be further proven so in the Mayo trials. It seems to be a good bet that it will take CEA's business. Why not replace a current tet that has the same draw backs but cheaper and with better accuracy? Seems to be a no-brainer in book.
News 
Market Data 
Discover 
